Class Action Lawsuit Announced for Novo Nordisk A/S Shareholders: Important Deadlines Ahead

Alert for Novo Nordisk A/S Shareholders

In an important notice to investors, The Gross Law Firm has announced a class action lawsuit regarding Novo Nordisk A/S (NYSE: NVO). The firm is inviting shareholders who acquired shares during the class period—from May 7, 2025, to July 28, 2025—to reach out if they are interested in being appointed as lead plaintiffs. This move aims to provide some avenue for recovery for those impacted by the company’s recent misstatements.

Allegations Against Novo Nordisk

The lawsuit's allegations center on the claims that Novo Nordisk’s leadership made excessively positive statements regarding the company's market potential while withholding critical information from shareholders. Specifically, it is alleged that the company significantly underrepresented the adverse effects of the market dynamics affecting GLP-1 medications, such as Wegovy and Ozempic. Furthermore, the firm claims that there was a significant overstatement regarding the likelihood of consumers switching to Novo's branded alternatives, misleading investors about the company’s true growth capabilities and market penetration potential.

On July 29, 2025, Novo Nordisk publicly announced a drastic downward revision of its sales and profit forecasts, which stemmed from lowered growth expectations for the latter half of 2025. This news triggered a notable decline in the company's stock price, plummeting from $69.00 per share to $53.94 per share, representing a staggering drop of approximately 21.83% within just a day. Such drastic changes indicate the impact that inaccurate disclosures can have on investor confidence and market valuations.

Important Dates for Shareholders

The deadline for shareholders interested in participating in this class action is September 30, 2025. It is imperative for those who purchased shares within the stipulated period to register their details to ensure they do not miss any chance for potential recourse. Interested parties can register through The Gross Law Firm's official website and should act promptly to secure their rights as shareholders.

What To Expect After Registration

Once registered, shareholders will be enrolled in a comprehensive portfolio monitoring software that provides real-time updates on the status of the case. Notably, the appointment as a lead plaintiff is not a prerequisite for participating in any recovery efforts, allowing more flexibility for interested investors.

Why Choose Gross Law Firm?

The Gross Law Firm has gained national recognition for its dedicated efforts aimed at protecting investors' rights. With a strong focus on holding corporations accountable for misleading practices, the firm emphasizes its commitment to supporting investors affected by corporate misconduct. Their legal expertise helps ensure that companies uphold responsible business practices, aiming always to uphold investor interests and integrity in the financial markets. John Doe, a representative from the firm, reaffirmed that the dedication to investor rights is at the core of their mission.

For further assistance or questions, shareholders of Novo Nordisk can reach out directly to The Gross Law Firm based in New York. Their contact information as listed below might be useful for those pondering next steps.

Contact Details

The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

Don't delay if you believe you've been impacted; register today and protect your rights as an investor.